Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

NCT00596245 | Completed Phase 1 DMC

• 1 other identifier: MT400-108
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, parallel group, single-center study. The study design consists of a screening and a treatment period. A total of 42 (approximately 21 of each sex) non-smoking healthy volunteers aged 18 - 35.

Conditions

Healthy

Keywords

non-smoking healthy volunteers aged 18 - 35

Outcome Measures

Primary Outcomes (1)

• The primary objective is to assess the impact on production of chromosomal aberration after dosage of MT 400 or naproxen sodium versus placebo. Comparison of post-dose chromosomal aberration rates will also be made to baseline rates within each arm.

  7 days

Secondary Outcomes (1)

• Potential subjects will be assessed for exposure to ionizing radiation or working with cytotoxic chemicals.

  7 days

Study Arms (1)

1

EXPERIMENTAL

MT 400, naproxen sodium 550mg

Drug: MT400

Interventions

MT400 DRUG

MT 400, naproxen sodium 550mg

1

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects who are 18-35 years of age at the screening visit
• Female subjects are eligible for participation in the study if they are of:
• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
• Childbearing potential, have a negative pregnancy test (urine) at Screening, and at least one of the following applies or is agreed to by the subject:
• Female sterilization or sterilization of male partner; or,
• Any non-medicated intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year; or,
• Barrier method
• Physical status within normal limits for age and consistent with observations at Screening
• Subject agrees to remain sequestered on site during the treatment phase of the study and is willing and able to abstain from the consumption or use of any alcohol, caffeine containing beverages or medication for the duration of the study
• Subject is able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed

You may not qualify if:

• History of hypersensitivity, allergy, intolerance or contraindication to the use of any triptan, NSAID or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma
• History or presence of cardio-or cerebrovascular disease; e.g., diabetes, hypertension, hyperlipidemia
• History or presence of congenital heart disease, cardiac arrhythmias requiring medication, or a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in the study
• History or evidence of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or sign/symptoms consistent with any of the above
• History or evidence of central nervous system pathology including stroke and/or transient ischemic attacks, epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening
• History or evidence of impaired hepatic or renal function or any screening laboratory assessment that is clinically significant in the investigator's opinion
• Has clinically significant allergic disease (excluding non-active hay fever) or a history of multiple drug allergies
• Evidence of macrocytic or microcytic anemia or deficiency of folate or B12 at Screening
• Blood donation in excess of: 500 mL in 14 days; 1,500 mL in 180 days or 2,500 mL in one year
• History of any bleeding disorder
• Gastrointestinal disorder, surgery, ulceration, or perforation in the past 6 months; gastrointestinal bleeding in the past year; or evidence or history of inflammatory bowel disease
• Females actively trying to become pregnant or breast feeding
• History or evidence of alcohol abuse (more than 28 units of alcohol (male) or 21 units of alcohol (female) per week) or substance abuse within the last year or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicate participation in this clinical trial
• Participated in a investigational drug trial within the previous four weeks
• Used tobacco products within the past year

Sponsors & Collaborators

• GlaxoSmithKline: lead
• POZEN: collaborator

Study Sites (1)

Matthew M. Medlock, MD

Austin, Texas, 78744, United States

Location

Study Officials

• Matthew M Medlock, MD

  PPD Development, LP

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2008
• First Posted: January 16, 2008
• Study Start: October 1, 2007
• Primary Completion: December 1, 2007
• Study Completion: December 1, 2007
• Last Updated: April 16, 2015

Record last verified: 2015-04

Locations

US (1)